| Title |
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
|
|---|---|
| Published in |
Journal of Hematology & Oncology, February 2010
|
| DOI | 10.1186/1756-8722-3-5 |
| Pubmed ID | |
| Authors |
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo, Delong Liu |
| Abstract |
Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies. At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies. This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents. |
Mendeley readers
The data shown below were compiled from readership statistics for 233 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| Denmark | 2 | <1% |
| Brazil | 1 | <1% |
| Germany | 1 | <1% |
| Belgium | 1 | <1% |
| China | 1 | <1% |
| United States | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 223 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 52 | 22% |
| Researcher | 47 | 20% |
| Student > Master | 31 | 13% |
| Student > Bachelor | 19 | 8% |
| Student > Postgraduate | 14 | 6% |
| Other | 43 | 18% |
| Unknown | 27 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 93 | 40% |
| Medicine and Dentistry | 38 | 16% |
| Chemistry | 24 | 10% |
| Biochemistry, Genetics and Molecular Biology | 22 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Other | 14 | 6% |
| Unknown | 32 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2019.
All research outputs
#4,696,396
of 22,787,797 outputs
Outputs from Journal of Hematology & Oncology
#346
of 1,191 outputs
Outputs of similar age
#27,702
of 165,339 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 3 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,191 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,339 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them